Marina Grinenko

Ms. Marina Grinenko

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2026 in International Journal of Clinical and Experimental Medical Sciences
Verified
Journal Article
Open access
PDF file
MGMarina Grinenko
Marina Grinenko
ADAnastasia Doronenkova
Anastasia Doronenkova
AMAnastasia Marysheva
Anastasia Marysheva
IZIvan Zaigraev
Ivan Zaigraev
NKNikolay Krotenko
Nikolay Krotenko
LKLev Krichevskiy
Lev Krichevskiy
Cell-free DNA (cfDNA) and neutrophil extracellular traps (NETs), specifically marked by histone type 3.1, play a dual pathogenic role in sepsis by reflecting cellular damage and directly exacerbating tissue injury, highlighting their clinical relevance for extracorporeal elimination therapies. To evaluate their prognostic value, we conducted a prospective, single-center observational study quantifying nucleosomes containing histones of the H3.1 type (Nu.H3.1) in 52 adult patients with septic shock admitted to an intensive care unit between August 2023 and May 2024. The cohort (64% male) had a mean SOFA score of 10±4 and an APACHE II score of 22±7. The H3.1-nuc concentration was 4658 ± 3962 ng/mL, and the median cfDNA level was 3041 (876–7815) ng/mL. Statistical analysis revealed that Nu.H3.1 levels significantly and positively correlated with cfDNA (r=0.67; p=0.0001), serum lactate (r=0.4; p=0.004), and SOFA scores (r=0.41; p=0.002). Furthermore, Nu.H3.1 demonstrated significant predictive performance for both 28-day mortality (AUC=0.68; 95% CI: 0.53–0.84; p=0.037) and the development of acute kidney injury (AKI) (AUC=0.74; 95% CI: 0.57–0.90; p=0.014). In conclusion, Nu.H3.1 serves as an independent predictor of adverse outcomes in septic shock, with established threshold values identifying patients at high risk for mortality and AKI. These findings suggest that Nu.H3.1 is a promising biomarker for clinical risk stratification and for substantiating indications for the extracorporeal elimination of toxic DNA-associated structures from the systemic circulation.

11 August 2025 in Messenger of ANESTHESIOLOGY AND RESUSCITATION
Verified
Journal Article
Open access
PDF file
MGMarina Grinenko
Marina Grinenko
OIO. V. Ignatenko
O. V. Ignatenko
ADA. A. Doronenkova
A. A. Doronenkova
IZI. A. Zaigraev
I. A. Zaigraev
NKN. P. Krotenko
N. P. Krotenko
NPN. S. Pokrovskiy
N. S. Pokrovskiy
Introduction. Multiple studies were shown significant role of cell-free DNA (cfDNA) as a marker and mediator of the septic process. Excessive formation of cfDNA is associated with adverse clinical events, which allows to consider this structure as a potential target for therapy.The objective was to study the level of cell-free DNA in patients with septic shock, to evaluate the correlation of the cfDNA level with clinical and laboratory data of patients, and the incidence of acute kidney injury and mortality.Materials and methods. The prospective single-center observational pilot study included 52 patients over 18 years old with septic shock (Sepsis-3 criteria) admitted to the intensive care unit of the Moscow City Clinical Hospital named after S. S. Yudin of the Health Department of Moscow from August 2023 to May 2024.Results. The final number of patients included in the study was n = 52 (64% of men and 36% of women) aged 52.1 ± 17.3 years, with a severity score according to SOFA 10 ± 4 and Apache II 22 ± 7 points, respectively. The concentration of cfDNA was 3041 (876–7815.0) ng/ml. Correlation analysis revealed associations of various directions with clinical and laboratory data, the most significant was a moderately positive correlation with the level of lactate (rxy = 0.49, p < 0.0001) and creatinine (rxy = 0.42, p < 0.002). ROC curve analysis showed an association between the level of cfDNA and 28-day mortality (area under the curve 0.69, AUC 95% confidence interval (CI) (0.54–0.84), p = 0.031; cut off level – 1893 ng/ml; sensitivity – 72.2% and specificity – 62.5%). Conclusion. The study found that cfDNA had diagnostic value in septic shock, and the level of cfDNA correlated with clinical diagnostic data and significant clinical events in patients with septic shock.

30 January 2026 in Russian Sklifosovsky Journal "Emergency Medical Care"
Verified
Journal Article
Closed access
MGMarina Grinenko
Marina Grinenko
IZI. A. Zaigraev
I. A. Zaigraev
NKN. P. Krotenko
N. P. Krotenko
MAM. I. Afanasieva
M. I. Afanasieva
ADA. A. Doronenkova
A. A. Doronenkova
NPN. S. Pokrovskyi
N. S. Pokrovskyi
Introduction. Extracellular DNA (exDNA) is a well-known but poorly understood mediator of sepsis. The aim was to investigate the role of exDNA as an independent predictor of mortality and as a marker of unfavorable clinical phenotype for patients with septic shock. Material and methods. The patients over the age of 18 with septic shock (Sepsis-3 criteria) who were admitted to the intensive care unit of the S.S. Yudin City Clinical Hospital between August 2023 and May 2024 were included in a prospective observational study. Results. Total of fifty-two patients (64% men, 36% women) aged 52.1 ± 17.3 years, with severity of the condition on the SOFA score 10±4 and APACHE II score — 22±7 were included. The exDNA concentration was 3041 (876–7815.0) ng/ml. For exDNA, a significant (p=0,031) association with 28-day mortality was determined (AUC 0.69, 95% CI (0.54–0.84)), and a cut-off point >1893 ng/ml was identified, at which the OR of the hospital death corresponded to 4.3 (95% CI 1.3–15.1, p=0.03). The dependence of the risk of death on the concentration of exDNA (1893 ng/ml), estimated using the Mantel-Cox log-rank test, was statistically significant (p=0.028). The median survival time in the exDNA group >1893 ng/ml was 7 days, and for exDNA levels 1893 ng/ml in patients with septic shock were the level of mixed venous blood lactate (OR 2.0; 95% CI [1.02, 3.92], p=0.044) and SOFA score (OR 1.23; 95% CI [1.02, 1.47], p=0.029). Conclusion. The exDNA level is an independent predictor of mortality in septic shock. Its cut-off point of 1893 ng/ml could be considered as an indication for extracorporeal elimination of exDNA. Point of care laboratory markers of a significant increase in the blood concentration of exDNA were also identified and could be considered as a guide to an intensive care.

31 January 2026 in Annals of Critical Care
Verified
Journal Article
Open access
PDF file
OIO. V. Ignatenko
O. V. Ignatenko
ADA. A. Doronenkova
A. A. Doronenkova
AMA. N. Marysheva
A. N. Marysheva
IZI. A. Zaigrayev
I. A. Zaigrayev
MGMarina Grinenko
Marina Grinenko
LKLev А. Krichevskiy
Lev А. Krichevskiy
INTRODUCTION: The consistently high mortality rate associated with septic shock leads to the search for new treatment strategies. OBJECTIVE: The aim of our study was to analyze the efficacy and safety of the combined use of plasma exchange and hemosorbtion in septic shock. MATERIALS AND METHODS: A total of 64 patients with septic shock who were hospitalized in the ICU of the S.S. Yudin Hospital in Moscow from January 2023 to January 2024 were prospectively examined. The combined extracorporeal therapy group included patients who underwent two combinations of procedures depending on the level of endotoxinactivity (endotoxin activity assay — EAA): with EAA greater than 0.6 — plasma exchange + LPS hemosorbtion, with EAA less than 0.6 — plasma exchange + cytokine hemosorption. The controlgroup included patients with standard sepsis therapy. Clinical and laboratory parameters, duration and outcomes of intensive care were recorded. RESULTS: The study group (ET, n = 31), compared with the control group (n = 33), was characterized by a significant (p < 0.05) reduction of organ disfunction according to the Sequential Organ Failure Assessment, and Acute Physiology and Chronic Health Evaluation II, scales, a decrease of systemic inflammation markers, and an increase of IgG level within 72 hours after inclusion in the study. Hospital mortality was lower in the ET group than in the control group 32 and 58 %, respectively: OR 0.35; 95% CI 0.12–0.98; p = 0.023. CONCLUSIONS: Combined extracorporeal therapy is an effective treatment strategy for septic shock, improving the results of its intensive care.

31 January 2026 in Annals of Critical Care
Verified
Journal Article
Open access
PDF file
MGMarina Grinenko
Marina Grinenko
ADA. A. Doronenkova
A. A. Doronenkova
AMA. N. Marysheva
A. N. Marysheva
IZI. A. Zaigraev
I. A. Zaigraev
NKN. P. Krotenko
N. P. Krotenko
LKLev А. Krichevskiy
Lev А. Krichevskiy
INTRODUCTION: Cell free DNA (cfDNA) is of considerable interest as a marker and pathogenesis factor in sepsis. Two processes are sources of cfDNA: cell death with the ingress of the contents of the cell nucleus into the bloodstream and the release of extracellular neutrophil traps (NETs). The marker of NETs formation is histone type 3.1. CfDNA and NETs in sepsis act in a dual role — they characterize the degree of cellular damage and the intensity of the inflammatory response, and at the same time they are etiological agents of these two processes. OBJECTIVE: This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing significant clinical events. MATERIALS AND METHODS: The prospective single-center observational study included 52 patients with septic shock (Sepsis-3 criteria), admitted to the intensive care unit. RESULTS: The total number of patients was n = 52, with the severity score SOFA 10 ± 4. The median concentration of Nu.H3.1 was 4658 ± 3962 ng/ml, cfDNA — 3041 (876–7815) ng/ml. The most significant correlations of Nu.H3.1 were recorded with the lactate level (rxy = 0.4; p = 0.004) and the SOFA scale (rxy = 0.41; p = 0.002). For Nu.H3.1, a significant association with 28-day mortality and AKI was determined. CONCLUSIONS: The study showed that the marker of NETs formation — the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream. Objective. This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing acute kidney injury (AKI) and 28-day mortality. Material and methods. The prospective single-center observational pilot study included 52 patients over 18 years old with septic shock (Sepsis-3 criteria), admitted to the intensive care unit of the State Healthcare Institution "City Clinical Hospital named after S.S. Yudin" between August 2023 and May 2024. Results. The total number of patients included in the study was n=52 (64% men, 36% women) aged 52.1 ± 17.3 years, with the severity scores SOFA 10±4 and Apache II - 22±7 points, respectively. The median concentration of Nu.H3.1 was 4658± 3962 ng/ml, cfDNA - 3041 (876-7815.0) ng/ml. The correlation between cfDNA and Nu.H3.1 had a noticeable direct relationship (r xy = 0.67, p = 0.0001). The most significant correlations of Nu.H3.1 were recorded with the lactate level (r xy = 0.4, p = 0.004) and the SOFA scale (r xy = 0.41, p = 0.002). For Nu.H3.1, a significant association with 28-day mortality (AUC 0.68, 95% CI (0.53-0.84) p = 0.037) and AKI (AUC 0.74, 95% CI (0.57-0.90) p = 0.014) was determined. The OR for the development of AKI at a concentration of Nu.H3.1> 2731 ng / ml was 6.0 (95% CI: 1.6-26.0, p < 0.018), sensitivity, specificity - 67% and 75%, respectively. For 28-day mortality at a concentration of Nu.H3.1 > 2731 ng / ml, the OR was 4.4 (95% CI: 1.2-15.6; p = 0.03), sensitivity, specificity - 67 and 79%, respectively. Conclusion. The study showed that the marker of NETs formation – the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream.